Navigation Links
Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
Date:5/5/2008

sed of 97.5% sterile water and 2.5% cross-linked polyacrylamide. The Aquamid(R) hydrogel is homogeneous: it contains no microparticles; hence its filling effect is due solely to the injected volume. Unlike particle-based fillers, the hydrogel does not rely on an intended foreign body reaction to achieve the desired augmentation. Therefore, the filling effect is immediate and predictable. Moreover, the hydrogel does not cause tissue hardening or fibrosis. No skin test is needed before treatment.

The hydrogel integrates completely into the tissue and does not migrate from the injection site. It stays soft, feels like a natural part of the tissue and follows tissue movements. Because the hydrogel does not degrade over time, it provides augmentation that lasts for years.

Aquamid(R) is available in 40 countries worldwide and is under clinical investigation in the United States. Aquamid is being studied in a double-blind, randomized, multi-center, 2-arm parallel study involving 315 patients in 13 centers comparing the effectiveness of Aquamid(R) and Restylane(R) for the aesthetic treatment of facial wrinkles/folds. Data from this trial will support a PMA application with the FDA.

About Aquamid(R)

Aquamid(R) is a soft volume filler that gives a natural look and feel. Produced using Contura's patented hydrogel technology, Aquamid(R) is composed of 97.5% sterile water and 2.5% cross-linked polyacrylamide. Aquamid(R) was approved in Europe in 2001 and is available in 40 countries worldwide. Over 300,000 Aquamid(R) injections have been performed to date. It is currently under clinical investigation in the U.S. for the aesthetic treatment of facial wrinkles/folds. Aquamid(R) is not approved for sale in the United States.

About Contura

Contura is a medical technology company based in Denmark that develops and commercializes soft tissue fillers. Contura's products -- Aquamid(R) for facial contouring and Bulkamid(R) for the treatment of fe
'/>"/>

SOURCE Contura
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine technology :

1. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
2. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
3. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
6. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
11. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... -- BD Biosciences, a segment of BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... of high-performance research flow cytometers. The BD ... most compact footprint in its class at just 30" x ... (76.2 cm). Recognizing that space is a valuable commodity in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
... DENVER, Nov. 12 Corgenix Medical Corporation (OTC Bulletin Board: ... today reported sales of $2,044,967 for the first fiscal quarter ... ended September 30, 2008, an increase of 2.2%. , The ... compared with an operating loss of $94,133 for the first ...
... WASHINGTON, Nov. 12 Women,s Health Weekly recently ... are working on nearly 1,000 life-changing medicines for diseases affecting ... the Pharmaceutical Research and Manufacturers of America ... Food and Drug Administration or are in human clinical trials. ...
Cached Medicine Technology:Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3Record Number of New Medicines in Development for Women 2
(Date:6/19/2013)... study led by researchers at The University of Texas ... to show remarkable promise for the treatment of relapsed ... recent interim findings of the 18-center Phase 2 study ... of Medicine . Previous interim findings were presented in ... Annual Meeting and Exposition. , Unprecedented results, ...
(Date:6/19/2013)... In a study published in the June 19 online ... team led by researchers from the University of California, ... cellular events that take place when cardiac regeneration occurs ... provide evidence that various cell lines in the heart ... cell types, than previously thought. , More importantly, the ...
(Date:6/19/2013)... A new understanding of the genetic process that ... of potentially dangerous lesions for some women, and also ... therapies in certain cases suggesting they could actually ... The analysis provides a clearer picture of the chromosomal ... papillomavirus sometimes leads to chronic infection and, in less ...
(Date:6/19/2013)... Iowa study reveals significant disparities between minority and ... abuse treatment programs. Moreover, these disparities vary widely ... suggest that for most states there,s something amiss," ... and biostatistics. "There are strong racial and ethnic ... substance abuse treatment programs successfully, and those disparities ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... , His Longevity with the Deadly Disease Inspires ... Sept. 4 When Jerry Lewis takes the stage again on Labor Day ... the same lung disease as he will be watching - and not just ... from the funny man who suffers from a not-so-funny and little known fatal ...
... following is the Labor Day message of Stuart Appelbaum. Appelbaum is president of ... www.rwdsu.org , , NEW YORK, Sept. 4 ... the worst of times and the best of times. , , ... and incompetence our country is now in the midst of its greatest economic ...
... SHENZHEN, China, Sept. 4 /PRNewswire-FirstCall/ - Hard to ... its China based subsidiary Mellow Hope, has just ... Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India. ... for the brain. It helps CNS in multiple ...
... social exclusion, have health problems, study suggests, , FRIDAY, ... considered a depressant, teetotalers as well as heavy drinkers ... than moderate tipplers, a new study has found. , ... don,t drink report having fewer friends than drinkers do, ...
... ... Chain Drug Stores (NACDS) President and Chief Executive Officer Steven C. Anderson, IOM, CAE ... First Circuit ruling on September 3, 2009, upholding the reduction of average wholesale prices ... Alexandria, ...
... SHENYANG, China, Sept. 4 /PRNewswire-Asia/ -- ... wholly-owned subsidiary of China,s,leading IT solutions & services ... its development strategy and new products,officially launching three ... 16 multi-slice CT scanner, Sparkler 1.5T superconductive MRI, ...
Cached Medicine News:Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 2Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 3Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 2Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Non-Drinkers More Likely to Be Anxious, Depressed 2Health News:NACDS: Court Ruling on AWPs Shifts "Urgency for Action" to States 2Health News:Neusoft Announces New Releases of Flagship Medical Products 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... the borders of stereomicroscopy with increase ... high-contrast images and significantly more image ... resolution and contrast. The innovative operating ... all essential functions of a stereomicroscope ...
Medicine Products: